

<sup>1</sup> Internal Medicine, Hennepin Healthcare, Minneapolis, Estados Unidos (EEUU)

<sup>2</sup> Gastroenterology and Hepatology, Centro de Enfermedades Hepáticas y Digestivas, Bogotá, Colombia

<sup>3</sup> Gastroenterology and Hepatology, Hospital Privado Universitario de Córdoba, Córdoba, Argentina

<sup>4</sup> Gastroenterology and Hepatology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Perú

<sup>5</sup> Gastroenterology and Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brasil

<sup>6</sup> Gastroenterology and Hepatology, Pontificia Universidad Católica de Chile, Santiago, Chile

<sup>7</sup> Gastroenterology and Hepatology, Universidad San Francisco de Quito, Quito, Ecuador

<sup>8</sup> Gastroenterology and Hepatology, Erasmus University Rotterdam, Rotterdam, Países Bajos

<sup>9</sup> Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Estados Unidos

**Introduction and Objectives:** Latin Americans experience some of the highest global rates of non-alcoholic fatty liver disease (NAFLD) and the prevalence of cirrhosis is increasing in this population. The rs641738 C>T single nucleotide polymorphism (SNP) of MBOAT7 has been associated with NAFLD development and cirrhosis in Europeans with NAFLD. However, the impact of this SNP in Latin Americans is unclear. We aimed to evaluate a cohort of Latin Americans with NAFLD to determine if MBOAT7 effects the risk of cirrhosis in this understudied population.

**Materials and Methods:** Individuals with NAFLD from 6 South American countries (Argentina, Ecuador, Brazil, Chile, Peru and Colombia) were prospectively recruited via the ESCALON network. Genotyping was performed with the TaqMan-genotyping assay. Genotype frequencies for MBOAT7 were compared using chi-square. Those with hepatocellular carcinoma were excluded.

**Results:** A total of 278 patients were included, 189 with cirrhosis and 89 without cirrhosis. 55% of the cirrhosis cohort were females compared to 61% of the cohort without cirrhosis ( $p=0.337$ ). The median ages of those with and without cirrhosis were 64 (IQR 59-70) and 60 years (IQR 52-65), respectively. The MBOAT7 TT genotype was present in 36/189 (19%) of subjects with cirrhosis and 7/89 (8%) of subjects without cirrhosis (OR=2.76, 95% CI: 1.17-6.47,  $p=0.016$ ). We evaluated the minor allele frequency (MAF) of MBOAT7 in our cirrhosis cohort compared to the Latin American population in the gnomAD database, a genome database with 17,720 sequences belonging to Latin Americans. MAF was elevated in cirrhotics compared to the general Latin American population (43% vs. 33% respectively, OR=1.54, 95% CI: 1.25-1.89,  $p<0.001$ ).

**Conclusions:** The rs641738 C>T SNP of MBOAT7 was associated with cirrhosis in a cohort of Latin Americans with NAFLD. Identification of genetic risk factors for liver disease may lead to improved risk stratification and interventional strategies in this population with an increasing burden of liver disease.

<https://doi.org/10.1016/j.aohep.2023.101254>

## O- 5 HCC RISK SCORE PRE AND POST SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS TREATED FOR CHRONIC HEPATITIS C

Marcus Vinícius de Acevedo Garcia Gomes<sup>1</sup>, Diogo Delgado Dotta<sup>1</sup>, Manuella Andrade Oliveira Sobral<sup>1</sup>, Carla Brígido Oliveira<sup>1</sup>, Isabela Bodaczny Taliberti<sup>1</sup>, Nadjanine Linhares Casimiro<sup>1</sup>, Glenda Alves Pereira Oliveira<sup>1</sup>,

André Luís Ferreira Bruder<sup>1</sup>, Rosa Maria Nascimento Marcusso<sup>2</sup>, Betania da Silva Rocha<sup>1</sup>, Alexandre Trazzi<sup>1</sup>, PATRICIA ZITELLI<sup>1</sup>, Mário Guimarães Pessoa<sup>1</sup>

<sup>1</sup> Gastroenterologia e Hepatologia Clínica, Hospital das Clínicas da Universidade de São Paulo da Faculdade de Medicina, São Paulo, Brasil

<sup>2</sup> Bioestatística, Instituto de Infectologia Emílio Ribas, São Paulo, Brasil

**Introduction and Objectives:** Introduction: Patients with hepatitis C virus (HCV) with advanced fibrosis (F3/4) still presented a significant risk of developing hepatocellular carcinoma (HCC). There are models for HCC risk prediction, such as the HCC risk score developed by Iannou *et al* 2018. This study aimed to evaluate the prevalence and risk factors for hepatocellular carcinoma development in previously treated chronic HCV patients in an outpatient hepatology clinic at Hospital das Clínicas of University of São Paulo School of Medicine, Brazil.

**Materials and Methods:** This is a retrospective, observational and descriptive study in a series of 267 HCV patients. Review of patients' medical records, applying HCC risk score immediately before and 6 months after SVR, excluding cases with insufficient data and HCC before treatment of HCV. Data collection is still in progress and final results will be available at presentation.

**Results:** The total sample of this study consists of 267 patients, of whom, 127 (47.6%) had F4 degree fibrosis. Overall, 17 patients developed HCC after a median follow up period of 3 years (6.4%). The mean of HCC risk score at 3 years calculated in pre treatment was 9.64% and post treatment was 4.32% ( $p=0.002$ ). An accuracy of this score was slightly better in the pre treatment (AUROC=0.72) versus post treatment (AUROC=0.69) (Figure 1).

**Conclusions:** HCC risk score post treatment declines more than 50% compared to pre treatment of HCV, as expected in patients with HCV cure.




Figure 1. Pre- and post-treatment HCV HCC risk score accuracy

<https://doi.org/10.1016/j.aohep.2023.101255>

## O-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA

Luis Antonio Díaz<sup>1</sup>, Francisco Idalsoaga<sup>1</sup>, Gustavo Ayares<sup>1</sup>, Jorge Arnold<sup>1</sup>, Katherine Maldonado<sup>2</sup>, María Ayala<sup>3</sup>, Diego Perez<sup>2</sup>, Jaime Gomez<sup>3</sup>, Rodrigo Escarate<sup>3</sup>, Eduardo Fuentes<sup>1</sup>, Juan Pablo Roblero<sup>4</sup>, Blanca Norero<sup>5</sup>, Raul Lazarte<sup>6</sup>, José Antonio Velarde<sup>7</sup>, Janett Jacobo<sup>8</sup>, Jacqueline Córdova<sup>8</sup>, Fátima Higuera-de-la-Tijera<sup>9</sup>, Jesús Varela<sup>10</sup>, Scherezada Mejía<sup>11</sup>, Rita Silva<sup>12</sup>, Cristina Melo<sup>13</sup>, Roberta C. Araujo<sup>14</sup>, Gustavo Henrique Pereira<sup>15</sup>, Claudia Couto<sup>16</sup>,

Fernando Bessone<sup>17</sup>, Mario Tanno<sup>17</sup>,  
Gustavo Romero<sup>18</sup>, Manuel Mendizabal<sup>19</sup>,  
Sebastián Marciano<sup>2</sup>, Gonzalo Gomez<sup>20</sup>,  
Melisa Dirchwolf<sup>21</sup>, Pedro Montes<sup>22</sup>,  
Patricia Guerra<sup>23</sup>, Geraldine Ramos<sup>23</sup>,  
Juan Carlos Restrepo<sup>24</sup>, Enrique Carrera<sup>25</sup>,  
Mayur Brahma<sup>26</sup>, Ashwani Singal<sup>27</sup>,  
Ramón Bataller<sup>28</sup>, Vijay Shah<sup>29</sup>, Patrick S. Kamath<sup>29</sup>,  
Marco Arrese<sup>1</sup>, Juan Pablo Arab<sup>30</sup>

<sup>1</sup> Department of Gastroenterology, Pontificia  
Universidad Católica de Chile, Santiago, Chile

<sup>2</sup> Gastroenterology Unit, Roosevelt Hospital, Ciudad de  
Guatemala, Guatemala

<sup>3</sup> Servicio Medicina Interna, Hospital El Pino, Santiago,  
Chile

<sup>4</sup> Sección Gastroenterología, Hospital Clínico  
Universidad de Chile, Santiago, Chile

<sup>5</sup> Servicio de Gastroenterología, Hospital Sótero del Río,  
Santiago, Chile

<sup>6</sup> Servicio de Gastroenterología, Clínica Hospital del  
Profesor, Santiago, Chile

<sup>7</sup> Hospital Civil Guadalajara, Guadalajara, México

<sup>8</sup> Hospital General Manuel Gea González, Mexico City,  
México

<sup>9</sup> Servicio de Gastroenterología, Hospital General de  
México "Dr. Eduardo Liceaga, Mexico City, México

<sup>10</sup> Hospital Dublán, Chihuahua, México

<sup>11</sup> Hospital Juárez de México, Mexico City, México

<sup>12</sup> Unidade de Transplante de Fígado e do Hospital de  
Base, Faculdade de Medicina de São Jose do Rio Preto,  
Sao Paulo, Brasil

<sup>13</sup> Fhaz Fundação Hospital Adriano Jorge, Amazonas,  
Brasil

<sup>14</sup> Hospital das Clínicas da Faculdade de Medicina de  
Ribeirão Preto, Ribeirão Preto, Brasil

<sup>15</sup> Hospital Federal de Bonsucesso, Rio de Janeiro, Brasil

<sup>16</sup> Hospital das Clínicas Universidade Federal de Minas  
Gerais, Belo Horizonte, Brasil

<sup>17</sup> Hospital Provincial del Centenario, Santa Fe,  
Argentina

<sup>18</sup> Hospital de Gastroenterología " Dr. Carlos Bonorino  
Udaondo", Buenos Aires, Argentina

<sup>19</sup> Hospital Universitario Austral, Buenos Aires,  
Argentina

<sup>20</sup> Hospital Italiano Buenos Aires, Buenos Aires,  
Argentina

<sup>21</sup> Unidad de Trasplante Hepático, Hospital Privado de  
Rosario, Rosario, Argentina

<sup>22</sup> Hospital Nacional Daniel Alcides Carrión - Callao,  
Bellavista, Perú

<sup>23</sup> Instituto Gastroenterológico Boliviano- Japonés,  
Cochabamba, Bolivia

<sup>24</sup> Hospital Pablo Tobon Uribe, Medellin, Colombia

<sup>25</sup> Hospital Especialidades Eugenio Espejo, Quito,  
Ecuador

<sup>26</sup> Univeristy of Calgary, Alberta, Canadá

<sup>27</sup> Department of Medicine, University of South Dakota  
Sanford School of Medicine, South Dakota, Estados  
Unidos

<sup>28</sup> Liver Unit, Hospital Clinic, Barcelona, España

<sup>29</sup> Division of Gastroenterology and Hepatology, Mayo  
Clinic, Minnesota, Estados Unidos

<sup>30</sup> Department Of Medicine, Division Of  
Gastroenterology, Western University, London Health  
Sciences Center, Ontario, Canadá

**Introduction and Methods:** Severe alcohol-associated hepatitis (AH) is frequently associated with higher infection risk. This study aimed to assess the impact of infections in patients with AH in a multinational cohort in Latin America.

**Materials and Methods:** Multicenter prospective cohort study including patients with AH (2015–2022). We recorded clinical information, and the impact of infections was assessed using competing-risk models.

**Results:** We included 511 patients from 24 centers in 8 countries (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, and Peru). The mean age was 50.1±11.9 years, 426 (83.9%) were men, 264 (58.2%) had a previous diagnosis of cirrhosis, and the median MELD at diagnosis was 24.6 [19.6–30.6] points. Out of the total, 25.9% died, and only 3.7% underwent liver transplantation during follow-up. Also, 44.5% of patients developed an infection. Of them, 50.9% presented with infection at admission, 30.8% developed an infection during hospitalization, and 18.3% presented an infection in both situations. The most common localizations at admission were pulmonary (32.4%), urinary tract (33.1%), spontaneous bacterial peritonitis (15.9%), and cutaneous (9.7%). The main localizations during hospitalization were pulmonary (34.4%), urinary tract (25.8%), spontaneous bacterial peritonitis (14.0%), and bacteremia (8.6%). The incidence of multidrug-resistant (MDR) organisms was 11.2% at admission and 10.3% during hospitalization, while the incidence of extensively drug-resistant (XDR) organisms was 1.4% and 4.7%, respectively. The presence of infection was associated with higher mortality (sub-distribution hazard ratio [sHR] 1.92, 95%CI: 1.56–2.37; p<0.001). In a competing-risk model adjusted by age, sex, MELD, and ACLF grade, the infections were independently associated with mortality (sHR 1.33, 95%CI: 1.02–1.75; p=0.037).

**Conclusions:** Infections during an AH episode are frequent and independently associated with mortality in Latin America. However, the incidence of multidrug-resistant organisms was lower than in other regions. Efforts should be made to prevent, diagnose, and adequately treat infections in AH.

<https://doi.org/10.1016/j.aohep.2023.101256>

## O-7 CURRENT PRACTICE OF LIVER TRANSPLANTATION IN LATIN AMERICAN COUNTRIES: AN ALEH INTEREST GROUP SURVEY 2023

Paulo Bittencourt<sup>1</sup>, Liana Codes<sup>1</sup>, Adrian Gadano<sup>2</sup>,  
Alejandra Villamil<sup>2</sup>, Alfeu de Medeiros Fleck Jr<sup>3</sup>,  
Álvaro Urzua<sup>4</sup>, Debora Raquel Terrabuio<sup>5</sup>,  
Eira Cerda<sup>6</sup>, Graciela Elia Castro Narro<sup>7</sup>,  
Ignacio Roca<sup>8</sup>, John Abad González<sup>9</sup>, Josefina Pages<sup>10</sup>,  
Juan Carlos Restrepo Gutierrez<sup>11</sup>,  
Leonardo de Lucca Schiavon<sup>12</sup>, Mario Uribe<sup>13</sup>,  
Martin Padilla<sup>14</sup>, Norma Marlene Perez Figueroa<sup>15</sup>,  
Pablo Coste Murillo<sup>16</sup>, Raquel Stucchi<sup>17</sup>,  
Ricardo Chong<sup>18</sup>, Rodrigo Wolff<sup>19</sup>,  
Victoria Mainardi<sup>20</sup>, Rodrigo Zapata<sup>21</sup>

<sup>1</sup> Portuguese Hospital, Salvador, Bahia, Brasil

<sup>2</sup> Italian Hospital, Buenos Aires, Argentina

<sup>3</sup> Adult Liver Transplant Group, Santa Casa  
Misericórdia, Porto Alegre, Rio Grande do Sul, Brasil

<sup>4</sup> Clinical Hospital, University of Chile, Santiago, Chile

<sup>5</sup> Clinical Hospital, University of São Paulo, São Paulo,  
Brasil

<sup>6</sup> Central Military Hospital, Mexico City, México

<sup>7</sup> National Institute of Medical Sciences and Nutrition  
Salvador Zubirán, Mexico City, México

<sup>8</sup> El Cruce Hospital, Buenos Aires, Argentina